Striatal dopamine D2 receptor availability in OCD with and without comorbid social anxiety disorder: Preliminary findings

Depression and Anxiety

Volumn 25, Issue 1, 2008, Pages 1-7

  Schneier, Franklin R ^a,b   Martinez, Diana ^a,b   Abi Dargham, Anissa ^a,b   Zea Ponce, Yolanda ^a,b   Blair Simpson, H ^a,b   Liebowitz, Michael R ^a,b   Lamelle, Marc ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

Detachment; Dopamine; IBZM; Neuroreceptor imaging; Obsessive compuhive disorder; Social phobia; SPECT

Indexed keywords

DOPAMINE 2 RECEPTOR; IODINE 123; IODOBENZAMIDE DERIVATIVE; IODOBENZAMIDE I 123; IODOBENZOIC ACID DERIVATIVE; TRACER; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DOPAMINE RELEASE; FEMALE; HORMONE RECEPTOR INTERACTION; HUMAN; KAROLINSKA SCALE OF PERSONALITY; MALE; NEUROBIOLOGY; OBSESSIVE COMPULSIVE DISORDER; PERSONALITY DISORDER; PRIORITY JOURNAL; RATING SCALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIAL PHOBIA;

ADOLESCENT; ADULT; AGE OF ONSET; BENZAMIDES; COMORBIDITY; CONTROL GROUPS; CORPUS STRIATUM; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINE; HUMANS; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PERSONALITY ASSESSMENT; PERSONALITY INVENTORY; PHOBIC DISORDERS; PSYCHIATRIC STATUS RATING SCALES; PYRROLIDINES; RECEPTORS, DOPAMINE D2; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 38949186029     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20268     Document Type: Article

References (41)

1. Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR. 2002. Efficacy of olanzapine in social anxiety disorder: A pilot study. J Psychopharmacol 16:365-368.
2. Berridge KC, Aldridge JW, Houchard KR, Zhuang X. 2005. Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: A model of obsessive compulsive disorder and Tourette's. BMC Biol 3:4.
3. 2 receptor density and personal detachment in healthy subjects. Am J Psychiatry 155:1440-1442.
4. Carrasco JL, Hollander E, Schneier F, Liebowitz MR. 1992. Outcome of obsessive-compulsive disorder with comorbid social phobia. J Clin Psychiatry 53:387-391.
5. Crino RD, Andrews G. 1996. Obsessive-compulsive disorder and Axis I comorbidity. J Anxiety Disord 10:37-46.
6. 2 receptor Taq1 A2 allele and low activity COMT allele with obsessive-compulsive disorder in males. Eur Neuropsychopharmacol 6:446-450.
7. Denys D, de Geus F, van Megen HJ, Westenberg HG. 2004a A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65:1040-1048.
8. 2 receptor binding in obsessive-compulsive disorder. Biol Psychiatry 55:1041-1045.
9. 2 dopamine receptors and personality traits. Nature 385:590.
10. First MB, Spitzer RL, Gibbon M, Williams JBW 1994. Structured Clinical Interview for Axis I DSM-IV Disorders - Patient edition (SCID - 1/P, Version 2.0). New York: Biometrics Research Department, New York Psychiatric Institute.
11. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. 1989. The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011.
12. 2 receptor binding characteristics in cynomolgus monkeys assessed with positron emission tomography. Synapse 29:80-83.
13. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
14. Hemmings SMJ, Kinnear CJ, Lochner C, Niehaus DJH, Knowles JA, Moolman-Smook JC, Corfield VA, Stein DJ. 2004. Early- versus late-onset obsessive-compulsive disorder: Investigating genetic and clinical correlates. Psychiatry Res 128:175-182.
15. Hesse S, Müller U, Lincke T, Barthel H, Villmann T, Angermeyer MC, Sabri O, Stengler-Wenzke K 2005. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res 140:63-72.
16. Johnson MR, Lydiard RB, Zealberg JJ, Fossey MD, Ballenger JC. 1994. Plasma and CSF HVA levels in panic patients with comorbid social phobia. Biol Psychiatry 36:426-427.
17. Kim C-H, Koo M-S, Cheon K-A, Ryu Y-H, Lee J-D, Lee H-S. 2003. Dopamine transporter density of basal ganglia assessed with [123]IPT SPET in obsessive-compulsive disorder. Eur J Mucl Med Mol Imaging 30:1637-1643.
18. King R, Mefford I, Wang C, Murchison A, Caligari E, Berger P. 1986. CSF DA levels correlate with extraversion in depressed patients. Psychiatry Res 19:305-310.
19. Laakso A, Vilkman H, Kajander J, Bergman J, Haaparanta M, Solin O, Hietala J. 2000. Prediction of detached personality in healthy subjects by low dopamine transporter binding. Am J Psychiatry 157:290-292.
20. 123I]iomazenil binding to benzodiazepine receptors in nonhuman primates: II: Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters. J Cereb Blood Flow Metab 14:453-465.
21. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, Innis RG. 1995. SPECT imaging of dopamine release after amphetamine challenge. J Nucl Med 36:1182-1190.
22. Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, Seibyl JP, Zoghbi SS, Bowers MB, Jatlow P, Charney DS, Innis RB. 1997. Imaging D-2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacol 17:162-174.
23. Liebowitz MR. 1987. Social phobia. Mod Probl Pharmacopsychiatry 22:141-173.
24. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies SO, Gully B, Klein DF. 1992. Phenelzine vs. atenolol in social phobia: A placebo controlled comparison. Arch Gen Psychiatry 49:290-300.
25. Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L. 1999. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry 156:1409-1416.
26. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, Huang Y, Simpson N, Ngo K, Van Heertum R, Laruelle M. 2001. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D2 receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21:1034-1057.
27. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. 2000. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57:794-801.
28. Mikkelsen EJ, Detlor J, Cohen D. 1981. School avoidance and social phobia triggered by haloperidol in patients with Tourette's disorder. Am J Psychiatry 138:1572-1576.
29. 2 receptors and cocaine self-administration. Nat Neurosci 5:169-174.
30. Pallanti S, Quercioli L, Rossi A, Pazzagli A. 1999. The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. J Clin Psychiatry 60:819-823.
31. Pezze MA, Feldon J. 2004. Mesolimbic dopaminergic pathways in fear conditioning. Prog Neurobiol 74:301-320.
32. Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. 2003. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60:1130-1135.
33. Schalling D, Asberg M, Edman G, Oreland L. 1987. Markers for vulnerability to psychopathology: Temperament traits associated with platelet MAO activity. Acta Psychiatr Scand 76:172-182.
34. Schneider F, Weiss U, Kessler C, Muller-Gartner HW, Posse S, Salloum JB, Grodd W, Himmelmann F, Gaebel W, Birbaumer N. 1999. Subcortical correlates of differential classical conditioning of aversive emotional reactions in social phobia. Biol Psychiatry 45:863-871.
35. 2 receptor binding potential in social phobia. Am J Psychiatry 157:457-459.
36. Schneier FR, Liebowitz MR, Laruelle M. 2001. Detachment and generalized social phobia [Letter]. Am J Psychiatry 158:327.
37. Spielberger CD. 1983. Manual for State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press.
38. Szechtman H, Sulis W, Eilam D. 1998. Quinpirole induces compulsive checking behavior in rats: A potential animal model of obsessive-compulsive disorder (OCD). Behav Neurosci 112:1475-1485.
39. Tiihonen J, Kuikka J, Bergstrom K, Lepola U, Koponen H, Leinonen E. 1997. Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 154:239-242.
40. 123I]β-CIT SPECT. Am J Psychiatry 161:2201-2206.
41. Villarreal G, Johnson MR, Rubey R, Lydiard RB, Ballanger JC. 2000. Treatment of social phobia with the dopamine agonist pergolide. Depress Anxiety 11:45-47.